Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension - MPR
Links shared publicly online about this topic.
- 1,420total visits
Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension - MPR
empr.com —
The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.
View full resource at empr.com
Tags: Heart Disease, High Blood Pressure, HIV Medication, Healthcare, FDA, Videx, Bristol-Myers Squibb
Most Recently Shared on January 29, 2010 at 10:01 pm By:
MPR News: Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension: The FDA has no... http://bit.ly/bRTWp9
FDA Alert: Videx/Videx EC (didanosine): Labeling Revision - Risk of Non-Cirrhotic Portal Hypertension
drugs.com — “FDA Alert: Videx/Videx EC (didanosine): Labeling Revision - Risk of Non-Cirrhotic Portal Hypertension” View full resource at drugs.com
Most Recently Shared on January 31, 2010 at 1:57 am By:
FDA Alert - FDA Warns of Non-Cirrhotic Portal Hypertension Risk in Patients Using Videx/Videx EC (didanosine) - http://bit.ly/cNElgB
Advertisement
